Chrysos Corporation has hit a new milestone with over one million samples processed monthly, driven by expanding lease agreements and deployments of its PhotonAssay technology. The company remains on track for FY26 revenue and EBITDA guidance amid accelerating global growth.
- Over one million samples processed monthly in March and April 2026
- 19 new PhotonAssay lease agreements signed year-to-date
- Expanded partnerships with ALS and Bureau Veritas
- 44 PhotonAssay units deployed globally with more in transit
- FY26 revenue and EBITDA guidance reaffirmed
Record Sample Volumes Highlight Growing Market Penetration
Chrysos Corporation Ltd (ASX:C79) has broken new ground by processing over one million samples in both March and April 2026, marking a significant step up in the utilisation of its PhotonAssay™ network. This milestone not only reflects heightened productivity but also underpins accelerated assay charge contributions, a key driver of the company's revenue and profitability.
The surge in sample volumes builds on the company's prior achievements, where nearly one million monthly samples were reported late last year, demonstrating sustained growth in assay throughput and market adoption. Such performance underlines Chrysos’ expanding footprint in the mining technology sector and its ability to scale operations effectively.
Expanding Global Footprint Through Strategic Partnerships
Year-to-date, Chrysos has inked 19 new lease agreements for its PhotonAssay units, including five since its last update, broadening its international reach. Notably, the company secured two additional agreements with ALS, boosting the partnership to 16 deployed units. Four of these new contracts pertain to ALS’s entry into new regional markets where it already operates laboratories.
In parallel, Chrysos extended its alliance with Bureau Veritas by signing a second lease agreement for deployment in Australia, complementing its initial South American installation. This expansion with one of the world's largest laboratory networks signals growing confidence in Chrysos’ technology across diverse geographies.
Direct-to-mine contracts are also gaining momentum, exemplified by Allied Gold's expanded engagement. The miner secured a subsequent lease for its Kurmuk mine in Ethiopia and an additional unit slated for deployment later this year, reinforcing Chrysos’ penetration into on-site assay services.
Fleet Growth and Operational Readiness for FY27
Deployment activity continues apace, with 44 PhotonAssay units now operational globally, including a recent installation at MSALABS in Grand Falls-Windsor, Canada. The company is actively shipping or staging eight additional units near deployment sites, supported by three more units completing factory acceptance testing. This pipeline positions Chrysos for an accelerated rollout in the 2027 financial year.
Current deployments include a unit in Chile, South America, further diversifying the geographic spread of Chrysos’ technology. This global momentum follows a strong first half FY26 performance, which featured a 49% revenue increase and a $200 million debt facility to underpin growth initiatives and capital expenditure.
Financial Guidance and Refinancing Progress
Chrysos remains confident in its FY26 financial outlook, reaffirming guidance of $80 million to $90 million in revenue and $20 million to $27 million in EBITDA, with performance tracking at the upper end of these ranges. This steady guidance comes amid ongoing fleet expansion and higher assay utilisation rates.
The company is also progressing a refinancing initiative targeting a total facility of $200 million, expected to close before 30 June 2026. This refinancing aims to support Chrysos’ aggressive deployment strategy and continued innovation in assay technology.
The combination of record sample processing, expanding partnerships, and robust financial positioning affirms Chrysos’ trajectory as a leading provider of mining assay solutions. Investors will be watching how these developments translate into sustained profitability and market share gains in the coming quarters.
Chrysos’ journey from near one million samples monthly last year to surpassing the one million mark twice in succession reflects a maturing technology gaining critical mass. The next challenge will be maintaining this growth momentum while navigating competitive pressures and operational scaling.
49% revenue growth and record PhotonAssay deployments underpin the company’s current confidence, but the market will be keen to see how Chrysos converts these operational metrics into sustained earnings and cash flow expansion.
Bottom Line?
Chrysos is capitalising on its PhotonAssay momentum with record volumes and expanding contracts, but execution of its deployment pipeline and refinancing will be critical to sustaining growth.
Questions in the middle?
- Can Chrysos sustain over one million samples monthly as deployments scale further?
- How will the $200 million refinancing impact Chrysos’ capital structure and growth initiatives?
- What is the potential for new direct-to-mine contracts to drive long-term revenue diversification?